Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert Samstein, Ronald P. DeMatteo, Chung‐Han Lee et al.|Nature Genetics|2019Cited by 4.4k
OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Nikolaus Schultz, Jianjiong Gao et al.|JCO Precision Oncology|2017Cited by 2.7k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Sophie Piperno‐Neumann, Josep M. Piulats et al.|New England Journal of Medicine|2021Cited by 869
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAlexander M. Menzies, Georgina V. Long, Douglas B. Johnson et al.|Annals of Oncology|2016Cited by 822
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodiesAlain P. Algazi, Ryan J. Sullivan, Katy K. Tsai et al.|Cancer|2016Cited by 375